Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program

RELMADA THERAPEUTICS, INC.

Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.
He will lead development of NDV-01, a gemcitabine/docetaxel sustained release formulation for NMIBC.
Company presented positive Phase 2 data at AUA 2025; Phase 3 trial expected to begin H1 2026.
Dr. Pruthi brings over 25 years experience in urologic oncology, including roles at enGene and J&J.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.